First Patient Dosed in Ph 1b/2 Trial of Samuraciclib + Vepdegestrant in Patients with Advanced Breast Cancer February 26, 2024
Dragonfly Announces Clinical Collaboration Exploring Combinations of DF1001 HER-2 TriNKET® with Trodelvy® in two Cancer Indications February 26, 2024
Avenzo Therapeutics Announces Global License Of AVZO-021 (ARTS-021), A Clinical Stage CDK2 Inhibitor From Allorion Therapeutics January 10, 2024
Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications January 10, 2024
Two Ph 3 Trials of Datopotamab Deruxtecan + Imfinzi Initiated in Patients Across Two Breast Cancer Subtypes January 10, 2024
First Patient Dosed In Ph1/2 Trial Of TNG348 In Patients With BRCA1/2-Mutant and Other HRD+ Cancers January 10, 2024
Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications January 6, 2024
Unprecedented Preliminary Survival and Clinical Benefit reported in Antibody-Drug Conjugate (ADC) Refractory Patient Subset treated with Bria-IMT™ regimen January 4, 2024
First Patient Dosed in Ph 2b Trial of Samuraciclib + Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer December 19, 2023
Jazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing Cancers December 11, 2023
Menarini Group and SciClone Pharmaceuticals to Develop and Commercialize ORSERDU® (Elacestrant) in China in Advanced or Metastatic Breast Cancer December 11, 2023
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor December 11, 2023
First Patient Enrolled in Ph 2 Study of BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu December 11, 2023
Interim Data from Ph 1b Trial of Vepdegestrant in Combination with IBRANCE Announced December 11, 2023
Latest Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence in patients with early breast cancer; supports regulatory submissions December 11, 2023
Inavolisib combination reduces the risk of disease progression by 57% in people with advanced HR+ve, HER2-neg breast cancer with a PIK3CA mutation December 11, 2023
Kadcyla shows significant OS benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment December 11, 2023
New Positive Interim Data from Dose Escalation and Ph 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients Announced December 11, 2023
U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer December 4, 2023
